4CMenB: from evidence to vaccination - Supported by GlaxoSmithKline Biologicals SA

Session Description:

The current level of evidence from 4CMenB safety, impact, and effectiveness has demonstrated that the vaccine consistently reduces invasive meningococcal B disease (MenB) across the most vulnerable age groups and in various settings. Prof Federico Martinón-Torres will be chairing the symposium, recent evidence from both infants and adolescents will be presented from Australia by Prof Helen Marshall, and the clinical relevance of these data and the evolution of meningococcal immunization programmes with MenB in Europe will be discussed by Prof Paolo Bonanni.

Managing invasive meningococcal disease (IMD): The short-term impact and future preventive perspectives - Supported by Sanofi Pasteur

Session Description:

This sponsored session will focus on raising awareness of the impact of invasive meningococcal disease (IMD) and advances in preventive strategies. The distinguished faculty will provide expert perspectives on the acute phase of disease and key challenges in diagnosis and critical care as well as discuss the most important unmet needs which still need to be addressed to reduce the burden of disease in infants, children and adolescents.

This satellite symposium specifically intended for healthcare professionals (HCPs) is sponsored by Sanofi on the occasion of the 39th Annual Meeting of the European Society for Paediatric Infectious Diseases, 24-29 May 2021. Individual medicinal products that may be referred to during this session may not be authorised/licensed or available in all countries. Content, where applicable, is based on the European Summary of Product Characteristics (SmPC). Please consult prescribing information in your country of practice, current to the date of viewing this session, as information may vary from country-to-country.